Clinical Trial Update: Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Steven E. Coutre | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-29